The most common AEs were nausea (54.2%), fatigue (45.8%), and alopecia (41.7%); ILD/pneumonitis was reported in 10.4% (5 of 48; 1 fatal case); however, these findings are limited by the relatively short duration of T-DXd treatment (median: HER2-positive, 6.5 months; HER2-low, 6.3 months) and follow-up (median: HER2-positive, 7.0 months; HER2-low, 6.9 months).71 Here, ERBB2 is linked to alopecia.